Which companies are Synmosa Biopharma's closest peers?

The cockpit's peer set: RPG Life Sciences (RPGLIFE.NS), Evolus (EOLS), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Shanghai Fudan Forward S&T (600624.SS), Jiangsu Bioperfectus Technologies (688399.SS), Aquestive Therapeutics (AQST), Aarti Drugs (AARTIDRUGS.NS), Beijing Centergate Technologies (Holding) (000931.SZ).

How has Synmosa Biopharma stock performed?

Over six months to 6 Nov 2026 the shares returned +1.6% against -16.4% for the median peer; over one year -8.0%.

← CockpitCompetitor Analysis › 4114.TWO Synmosa Biopharma CorpOpen in the cockpit ↗

Synmosa Biopharma Corp4114.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major

Momentum strong 67

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$442M

US dollars, full cap

Free float

82%

of shares outstanding

$/day

$981,480

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-0.1 pp

WACC 5.0%

Hurdle

-9 pp

Req g minus delivered

Next earnings

12 days

18 Nov 2026

Close · TWDNT$27.20

1D-2.0%

1W-5.6%

1M-6.4%

3M-6.4%

6M+1.6%

YTD-3.5%

1Y-8.0%

ATR %1.7%

52w lowhigh13.4% off high

What Synmosa Biopharma does

Employees: 586

Synmosa Biopharma at a glance

Size Synmosa Biopharma (4114.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $442M, the 490th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$27.20 on 6 Nov 2026.

Performance Over six months the shares gained 1.6%, against -16.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 11.4% over the last twelve months (peer median +5.5%); the operating margin is 10.7% (peer median 4.8%).

Valuation It trades at 2.5× enterprise value to sales against a peer median of 3.6× (8th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.1 points below its cost of capital (5.0% WACC).

Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Synmosa Biopharma against the median of its 20 peers (local-currency closes).

Synmosa Biopharma financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	NT$6.68B	NT$6.19B	NT$5.55B	NT$5.14B	NT$4.39B
Revenue growth	—	+12%	+8%	+17%	—
Gross profit	NT$2.61B	NT$2.54B	NT$2.25B	NT$1.97B	NT$1.69B
EBITDA	NT$1.07B	NT$1.12B	NT$1.08B	NT$956M	NT$780M
Net income	NT$827M	NT$822M	NT$685M	NT$595M	NT$799M
Free cash flow	NT$173M	NT$134M	NT$535M	NT$262M	NT$449M
Capital expenditure	NT$324M	NT$281M	NT$270M	NT$270M	NT$184M
Total debt	NT$3.36B	NT$2.52B	NT$2.55B	NT$2.44B	NT$3.37B

Quarterly statements and history in the cockpit →

Synmosa Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Synmosa Biopharma is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Synmosa Biopharma is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Synmosa Biopharma is the large dot.

Synmosa Biopharma competitors and peer comparison

How Synmosa Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Synmosa Biopharma against its 20 peers (data as of 6 Nov 2026)
Measure	4114.TWO	Peer median	Rank in peer set
1-month return	-6.4%	-13.7%	7th highest of 21
6-month return	+1.6%	-16.4%	7th highest of 20
Distance from 52-week high	-13.4%	-39.3%	2nd highest of 21
Revenue growth (TTM)	+11.4%	+5.5%	8th highest of 20
Operating margin	10.7%	4.8%	6th highest of 20
EV / Sales	2.5×	3.6×	8th cheapest of 20
Growth the price implies (Req g, 7 yrs)	6.5%	9.9%	4th least demanding of 10
Growth delivered (Del g)	+15.3%	+3.5%	2nd highest of 10
Hurdle (Req g minus delivered)	-8.7 pp	+3.8 pp	2nd least demanding of 10
ROIC minus cost of capital	-0.1 pp	-0.9 pp	8th highest of 19
EV / EBITDA	15.3×	19.1×	4th cheapest of 7
Net debt / EBITDA	0.5×	1.8×	3rd least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Synmosa Biopharma 4114.TWO	Taiwan	$442M	+2%	+11%	11%	2.5×	6.5%	+15.3%
RPG Life Sciences RPGLIFE.NS	India	$448M	+2%	+12%	18%	5.8×	n/a	n/a
Evolus EOLS	United States	$449M	+7%	+14%	-7%	1.8×	n/a	n/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ	China	$450M	+4%	-21%	8%	4.3×	23.7%	+28.2%
Shanghai Fudan Forward S&T 600624.SS	China	$450M	-4%	-14%	-34%	6.0×	n/a	n/a
Jiangsu Bioperfectus Technologies 688399.SS	China	$432M	-44%	-8%	-23%	5.7×	n/a	n/a
Aquestive Therapeutics AQST	United States	$454M	-16%	+13%	-114%	10.5×	n/a	n/a
Aarti Drugs AARTIDRUGS.NS	India	$430M	+12%	+15%	11%	1.6×	19.7%	+3.5%
Beijing Centergate Technologies (Holding) 000931.SZ	China	$430M	-20%	-16%	2%	2.0×	9.9%	+6.7%
Gufic Biosciences GUFICBIO.NS	India	$454M	+44%	+17%	14%	4.4×	n/a	n/a
Beijing Foyou Pharma 601089.SS	China	$455M	-24%	+5%	10%	0.2×	n/a	n/a
BlossomHill Therapeutics BLSM	United States	$429M	n/a	n/a	n/a	n/a	n/a	n/a
Lifecome Biochemistry 002868.SZ	China	$428M	-51%	-24%	-6%	7.0×	n/a	n/a
Phathom Pharmaceuticals PHAT	United States	$427M	-57%	+87%	-9%	2.9×	n/a	n/a
Puma Biotechnology PBYI	United States	$426M	+10%	-3%	13%	1.5×	2.8%	+0.3%
Dong-A Socio 000640.KS	South Korea	$425M	-11%	+10%	7%	0.7×	-8.8%	+12.8%
Zhejiang Chengyi Pharmaceutical 603811.SS	China	$463M	-21%	+7%	19%	3.6×	7.1%	+1.3%
Zhuhai Rundu Pharmaceutical 002923.SZ	China	$464M	-30%	+14%	5%	2.4×	2.5%	-1.3%
Shanghai Jiaoda Onlly 600530.SS	China	$464M	-22%	-2%	-2%	10.4×	33.5%	-0.9%
Teyi Pharmaceutical 002728.SZ	China	$465M	-9%	-7%	7%	3.5×	26.6%	+8.0%
Shaanxi Kanghui Pharmaceutical Co 603139.SS	China	$466M	-20%	-21%	-68%	9.0×	n/a	n/a

Questions

Which companies are Synmosa Biopharma's closest peers?: The cockpit's peer set: RPG Life Sciences (RPGLIFE.NS), Evolus (EOLS), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Shanghai Fudan Forward S&T (600624.SS), Jiangsu Bioperfectus Technologies (688399.SS), Aquestive Therapeutics (AQST), Aarti Drugs (AARTIDRUGS.NS), Beijing Centergate Technologies (Holding) (000931.SZ).
Is Synmosa Biopharma expensive compared with its peers?: On ev / sales it trades at 2.5× against a peer median of 3.6×, 8th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Synmosa Biopharma stock performed?: Over six months to 6 Nov 2026 the shares returned +1.6% against -16.4% for the median peer; over one year -8.0%.